Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

INTRODUCTION: Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis (IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large-scale post-marketing surveillance study is investigating the real-world tolerability/safety of nintedanib in Japanese pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Takashi, Inoue, Yoshikazu, Azuma, Arata, Homma, Sakae, Kondoh, Yasuhiro, Tanaka, Katsumi, Ochiai, Kaori, Sugiyama, Yukihiko, Nukiwa, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070295/
https://www.ncbi.nlm.nih.gov/pubmed/36692681
http://dx.doi.org/10.1007/s12325-022-02411-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070295/
https://www.ncbi.nlm.nih.gov/pubmed/36692681
http://dx.doi.org/10.1007/s12325-022-02411-y

Ejemplares similares